Chronic hepatitis B
Conditions
Interventions
Group A: treated with telbivudine from12 weeks of gestation,Telbivudine was discontinued at postpartum 12 weeks.
group B : treated with telbivudine from20 to 28 weeks of gestation,Telbivudine was discontinued at postpartum 12 weeks.
Group C:wasn’t given telbivudine treatment
Sponsors
Qingdao Chengyang People's Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 35 Years
Inclusion criteria
Inclusion criteria: 1. aged 20 to 35 years; 2. 12 weeks or 20-28 weeks of gestation; 3. patients with HBsAg-positive, HBeAg-positive, HBV DNA >=1.0*10^7 copies/ml; 4. alanine aminotransferase (ALT): 40 to 400 U/L; 5. good compliance.
Exclusion criteria
Exclusion criteria: 1. coinfection with other viruses during pregnancy: such as hepatitis A, C, D, E, human immunodeficiency virus, syphilis, toxoplasma gondii, rubella virus, cytomegalovirus, or simple herpesvirus infection; 2. The use of other antiviral drugs, immunosuppressive, cytotoxic drugs or corticosteroids during pregnancy ; 3. fetal deformity suggested by ultrasound examination; 4. genetic diseases; 5. gestational diabetes; serious respiratory, urinary, neurological comorbidity or combined with serious gastrointestinal diseases which affect drug absorption.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum levels of HBV DNA;ALT level;HBsAg positive rate;gestational age;body weight;head circumference;Apgar score; | — |
Secondary
| Measure | Time frame |
|---|---|
| the age of pregnant women;the disease duration years of pregnant women;the gravidity times and gestational of pregnent women; | — |
Countries
China
Contacts
Public ContactSUN WH
Outcome results
None listed